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THE ROLE OF CCAAT DISPLACEMENT PROTEIN IN NEUTROPHIL-SPECIFIC GENE 
EXPRESSION. Aimee Lee, Arati Khanna-Gupta and Nancy Berliner. Section of Hematology, 
Department of Internal Medicine, Yale University, School of Medicine, New Haven, CT. 
CCAAT displacement protein (CDP) is a highly conserved, ubiquitously expressed 
homeodomain protein with extensive homology to the Drosophila cut protein. CDP contains 
three conserved DNA-binding repeats called cut repeats, as well as a conserved homeodomain 
sequence. CDP is a transcriptional repressor of several developmentally regulated genes 
including gp91-phox, CCAAT enhancer binding protein epsilon (C/EBPs), and its 
downstream targets the neutrophil secondary granule proteins (SGPs), including lactoferrin 
(LF). We have previously shown that CDP binds to and represses both the C/EBPs and LF 
gene promoters, thereby preventing expression of SGPs both directly and indirectly. CDP 
overexpression represses expression of SGPs in 32Dcl3 cells, a murine myeloid cell line that 
undergoes differentiation in response to G-CSF stimulation. Several attempts at generating a 
CDP knockout mouse have been undertaken, but all have produced incomplete knockouts. I 
generated short hairpin RNA (shRNA) constructs to knock down CDP in 32Dwtl8 cells, 
which contain a chimeric G-CSF receptor linking the intracellular domain of the G-CSF 
receptor with the extracellular component of the erythropoietin (EPO) receptor, and 
differentiate in response to EPO. CDP repression in clones expressing the shRNA for CDP 
appears to correlate with increased LF expression in uninduced cells. Control clones do not 
express LF until induced with EPO for several days. The knockdown of CDP does not appear 
to affect the expression of C/EBPs, suggesting that LF expression reflects direct modulation 
of CDP binding to its promoter and is not an indirect effect of increased C/EBPs expression. 
This suggests that CDP can function as the sole negative regulatory element for LF gene 
expression, and that relief of CDP repression can increase LF expression independent of 
positive regulatory factors. 
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1 
Introduction 
Mature cells in all hematopoietic lineages are required for proper functioning of the adult 
mammal. The generation of mature neutrophils from hematopoietic stem cell (HSC) 
precursors is a process which is still incompletely understood. The basic model for 
formation of mature blood products from HSCs involves the regeneration of HSCs, as 
well as formation of precursors for other hematopoietic lineages. As a hematopoietic cell 
differentiates, it loses proliferative potential and gains specific characteristics of endstage 
mature cells. The HSC gives rise to both the common lymphoid progenitor (CLP) and 
common myeloid progenitor (CMP). The CMP further differentiates into the myeloid 
erythroid progenitor (MEP), which gives rise to megakaryocytes, basophils and 
eosinophils, and the granulocyte/macrophage progenitor (GMP), which gives rise to both 
monocyte and granulocyte precursors. 
To ensure a correct number of mature cells in each lineage, hematopoiesis is tightly 
regulated by many different cytokines and transcription factors (1,2). Granulocytes and 
monocytes originate from a common progenitor cell, but the precise mechanism by which 
the terminal products of maturation are formed is still unclear. Although granulocytes 
and monocytes share several transcription factors with overlapping functions, other 
factors will tip the balance in favor of producing either granulocytes or monocytes 
(reviewed in 1). PU.l, Spl and the CCAAT enhancer binding protein (C/EBP) family of 
transcription factors are shared transcription factors. Maf and Jun family members may 
favor the development of the monocyte lineage, while higher levels of C/EBPs could 

2 
direct the formation of neutrophil granulocyte precursors. The terminal maturation of 
neutrophils requires PU.l, C/EBPs (especially C/EBPs), Spl and retinoic acid receptors 
(RARs). The milieu is further enhanced by the presence of a variety of cytokines, or 
colony stimulating factors (CSFs) (reviewed in 2). In myeloid lineages, GM-CSF 
furthers the development of clones of granulocytes and macrophages, M-CSF stimulates 
production of macrophages, and G-CSF induces granulocyte formation. Interleukin-3 
(IL-3) can stimulate development of eosinophils, mast cells, megakaryocytes and 
erythroid cells in addition to producing macrophages and granulocytes. 
Granulocyte differentiation can be followed morphologically through phenotypic changes 
in the neutrophil nucleus, and biochemically through changes in cytoplasmic granule 
expression (Figure 1). Condensation of chromatin eventually transforms the immature 
myeloblast nucleus into the multilobed nucleus of a mature neutrophil. Biochemically, 
the promyelocyte is characterized by expression of primary “nonspecific” granules which 
contain myeloperoxidase (MPO). The transition between promyelocyte and myelocyte is 
marked by expression of secondary “specific” granule proteins (SGPs) such as lactoferrin 
(LF), neutrophil collagenase (NC), neutrophil gelatinase (NG), and transcobalmin 1 
(TCI) (3). Although expression of SGP mRNA and protein is coordinately upregulated 
at the promyelocyte to myelocyte transition, the genes themselves are physically unlinked 
(4). This suggests a coordinated and stage-specific upregulation presumably induced by 
common transcription factors that result in SGP gene expression. 
. 
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Figure 1. Neutrophil Maturation. Neutrophil maturation proceeds from the immature 
myeloblast to the segmented neutrophil. The morphological changes are paralleled by 
changes in granule protein expression. Figure courtesy of Arati Khanna-Gupta. 
Granule proteins formed at the same stage in development will sort into the same 
granules (5). One can then define the neutrophil developmental stage by the biochemical 
contents of the granules. Expression of SGPs serves as a marker for terminal myeloid 
differentiation (6). C/EBP epsilon (C/EBPs) contributes to the morphological and 
functional differentiation of neutrophils by upregulating SGP expression. Clinically, 
absence of SGPs or abnormal SGP expression is found in acute myelogenous leukemia 
(AML), myelodysplastic syndrome (MDS), and specific granule deficiency (SGD). All 
are associated with disruptions in normal myeloid differentiation. 
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In previous studies, our laboratory has demonstrated that a known negative regulator of 
transcription, CCAAT displacement protein (CDP) binds to the LF promoter and 
represses its transcription (7). In further studies, it was shown that CDP not only exerts 
these direct effects on the LF promoter, but also indirectly represses SGP expression by 
repressing C/EBPs (8). The overexpression of CDP inhibits expression of SGP genes in 
32Dcl3 cells, an IL-3 dependent murine myeloid cell line that undergoes differentiation 
in response to IL-3 withdrawal and G-CSF stimulation (9). Moreover, LF is not 
expressed in NB4 cells, a human acute promyelocytic cell line which contains the 
t(l5; 17) PML-RARa translocation. While CDP binding to the LF promoter is abolished 
in 32Dcl3 cells coincident with LF expression, CDP has been found to remain bound to 
the LF promoter in NB4 cells after morphological differentiation following ATRA 
induction. This suggests that decreased CDP binding to the LF promoter is necessary and 
permissive for LF gene expression. 
CDP is a highly conserved, ubiquitously expressed homeodomain protein with extensive 
homology to the Drosophila cut protein (reviewed in 10). The protein contains three 
highly conserved DNA-binding repeats called cut repeats (CR1-3), as well as a conserved 
homeodomain (HD) area (11) (Figure 2), which mediate its DNA binding capacity. CDP 
is a 350 kb gene with 33 exons (12) which maps to chromosome 7q22 (13). 
Rearrangements in 7q22 have been seen in AML, MDS and uterine leiomyomas, 
suggesting that CDP may function as a tumor suppressor gene (reviewed in 10). 
However, this hypothesis remains unproven. 
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Figure 2. Schematic drawing of CDP. CDP contains 3 cut repeats (CR) as well as a 
homeodomain region (HD). These 4 conserved areas mediate DNA binding activity. 
CDP is a negative regulator of several developmentally regulated myeloid genes, 
including gp91-phox, a component of the neutrophil respiratory burst NADPH oxidase 
complex (11). Interestingly, gp91-phox is expressed earlier than SGPs in myeloid 
differentiation. The mechanism by which CDP mediates this temporal gene regulation is 
currently unknown. Recent studies have shown that CDP cannot bind DNA as a 
monomer and that several splice isoforms of CDP exist (14). Different combinations of 
CR1-3 and HD, as well as variations in splicing, may account for the differential effects 
of CDP. Phosphorylation and recruitment of histone deacetylases have also been 
proposed as mechanisms contributing to the variety in CDP function (15,16). 
Our laboratory has previously demonstrated that CDP binds to and represses both the 
C/EBPe and LF promoters (7, 8). Overexpression of CDP leads to repression of SGPs in 
mouse and human cell lines without inhibiting morphological differentiation. Due to the 
size of the CDP gene several attempts at generating a CDP knockout mouse have been 
unsuccessful, generating partial knockouts each time. The ACR1 mouse, in which the 
first cut repeat has been deleted, exhibits a mild phenotype consisting of curly vibrissae. 
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wavy hair, and a high degree of pup loss most likely due to feeding difficulties (17). 
ACR3HD, displays partial neonatal lethality with survivors surrendering to a wasting 
disease within 2-3 weeks. Interestingly, they also display myeloid hyperplasia and 
lymphoid apoptosis (18). 
As generating a complete knockout of CDP has proven to be a difficult task, we decided 
to employ a PCR-based RNA interference (RNAi) strategy to attempt to knock-down 
CDP in myeloid cells. RNAi harnesses the cell’s inherent ability to degrade RNA from 
exogenous sources in a targeted manner. Several methods are available to produce RNAi 
in mammalian cells, including synthesized small interfering RNAs (siRNAs), in vitro 
RNAselll processed dsRNA, and short hairpin RNAs (shRNAs). I chose to use a vector- 
based shRNA strategy for several reasons: 1) the shRNA fragments are relatively simple 
to create and clone into appropriate vectors, 2) this strategy is more cost-effective than 
chemically synthesized siRNAs, 3) a vector-based strategy allows for the generation of 
stable cell lines, and 4) this method was previously successful in hematopoietic cell lines. 
A myeloid cell line in which CDP is knocked-down will provide valuable and more 
complete information on the role CDP plays in the developing neutrophil. 
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Hypothesis and Specific Aims 
The aim of this project is to characterize and define the role of CDP in myeloid 
differentiation using normal and leukemic cells as models. I proposed to perform a 
functional knockout of mouse CDP by utilizing short hairpin RNAs (shRNAs) to degrade 
CDP mRNA, thus preventing the formation of a final protein product. I hypothesize that, 
as SGP expression occurs at the same stage in differentiation yet the genes themselves are 
physically unlinked, SGP expression is regulated by shared transcription factors that 
direct the coordinate expression of SGPs during normal myeloid differentiation. I further 
hypothesize that one of these critical transcription factors is CDP. As transcriptional 
regulation of granulopoiesis is disrupted in AML, SGD and MDS, CDP must play an 
integral role in myeloid differentiation. The ultimate goal of this project will be to 
analyze the CDP knock down cells using a myeloid specific cDNA microarray generated 
in the Berliner Lab in collaboration with Dr. Arch Perkins (Dept of Pathology, Yale 
University School of Medicine). These analyses will shed light on all genes regulated by 
CDP during myeloid differentiation, and will provide valuable and more complete 
information on the role CDP plays in the developing neutrophil. 
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Methods 
Short Hairpin RNA (shRNA) vector construction. shRNA constructs were generated as 
previously described by Hannon (19, 20). Briefly, the group uses a PCR-based method to 
create generate vector-based RNA interference. A web based RNA oligonucleotide 
retriever was developed by the group, and interested researchers enter a nucleic acid 
accession number for the target gene. The web based program then designs an 
oligonucleotide which best targets future degradation of mRNA. shRNA design does not 
correlate with the location of cut repeats or HD (Figure 3). 
Mouse CDP ' 600 1,200 1,800 2*, 400 3,000 3,600 4,200 
oligo locationl 
t t tt 
2804-3031 3737-3901 
1667-1900 3353-3616 
700 1,400 2,100 2,800 3,500 4,200 4,900 
I I 
I lit 
2871-3185 3777-3946 
1695-1874 3420-3946 
, Location of cut repeat Q Location of shRNA 
Location of homeodomain 
Figure 3. Location of shRNA constructs in relation to cut repeats and 
homeodomain. shRNA constructs are targeted to the 5’ and 3’ ends of each gene. An 
additional site in the middle of the gene is targeted in the human CDP shRNA construct. 
None of the regions targeted by shRNA are known DNA-binding regions. 
Instead, the hairpin is designed in the most efficient location for RNAi degradation of 
mRNA. Oligonucleotides were made by the Oligonucleotide Synthesis Laboratory 
(Department of Pathology, Yale University) then used as the forward 5’ PCR primer. 
while another oligonucleotide which contains the U6 promoter sequence is used as the 3’ 
Human CDP 
oligo locatior| 

9 
primer (Figure 4). PCR with DMSO using the pGEM-Zeo-U6 vector as template was 
performed, then the PCR fragment was cloned using TOPO cloning (Invitrogen, 
Carlsbad, CA) for use in transient transfections. For stable transfections, the PCR 
fragment was subcloned into the GFP-containing MigRl vector (Figure 5). 
Sequencing 
Transient transfection into NIH-3T3 S' 
fibroblast cells to test shRNA constructs 
Subclone into MigRl vector 
I 
Transfect into 32Dwt18 cells 
Figure 4. shRNA Construction. As outlined in the text, forward and reverse PCR 
primers were developed based on the Hannon method. PCR fragments containing the 
shRNA were first cloned into the TA vector and subcloned into MigRl. 
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Figure 5. MigRl vector. The MigRl vector is 6056 bp in size and contains genes for 
ampicillin resistance as well as GFP driven by an IRES. The shRNA PCR fragment was 
cloned into the EcoR I and Bgl II restriction sites. 
Tissue culture. NIH3T3 cells were grown and maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) with 10% Fetal Calf Serum (FCS, Gemini Bio-products). 
32Dwtl8 cells were maintained in Iscove’s Modified Dulbecco Medium (IMDM) 
supplemented with 10% Fetal Bovine Serum (FBS, Gemini Bio-products) and 10% 
WEHI-3D-conditioned medium. All growth media were supplemented with 5U/mL 
penicillin, 5pg/mL streptomycin sulfate and 2mM L-glutamine. 
Transient transfection ofNIH3T3 cells. NIH3T3 cells were plated at a density of 1.5 x 
106 cells per 10 cm plate the day prior to transfection in DMEM with 10% FCS. The 
morning of transfection, cells were washed once with PBS, and then incubated in 
Optimem (Gibco). 1 Opg DNA was added to a mixture of 3pL Fugene 6 Transfection 
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Reagent (Roche, Indianapolis, IN) and Optimem to a total volume of lOOpL. Cells were 
incubated overnight in Optimem and DNA mixture, and then medium was changed to 
DMEM the following DNA. Cells were harvested 72 hours after transfection. 
Stable transfection of 32Dxvtl8 cells. Exponentially growing 32Dwtl8 cells (1.0 x 107) 
were washed twice with PBS and resuspended in 180pL HEPES-buffered saline. lOpg 
of DNA was transfected by electroporation. The electroporated cells were resuspended 
in IMDM supplemented with 10% WEHI-3D-conditioned medium and 10% FBS. 
Flow cytometry. 7 x 106 32Dwtl8 cells were washed in PBS and resuspended in IMDM 
supplemented with 10% WEHI-3D-conditioned medium and 2.5% FBS with propidium 
iodide to a final concentration of 2pg/mL. Cells were sorted by Mr. Rocco Carbone 
(Yale Cancer Center shared facility) and collected in 4 mL IMDM supplemented with 
10% WEHI-3D-conditioned medium and 10% FBS. 
Induction of differentiation. Stably transfected 32Dwtl8 cells were collected in growth 
medium (GM) for day 0 samples, or induced to differentiate in induction medium (IM) 
IMDM supplemented with 10% FBS without 10% WEHI-3D-conditioned medium, and 
addition of lU/mL EPO for 4 days. Media was replaced every 3 days during the 
induction procedure, and cell densities were maintained at or below 1.0 x 106 cells/mL. 
All growth media were supplemented with 5U/mL penicillin, 5pg/mL streptomycin 
sulfate and 2mM L-glutamine. 
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Cytospins. 1.0 x 104 cells were centrifuged at low speed onto a microscope slide and 
stained with Wright-Geimsa staining. 
Growth Curve Analysis. 1 x 105 cells were grown in regular growth medium, induced to 
differentiate with EPO, or grown in IMDM without WEHI-3D-conditioned medium. 
Cell densities were maintained at or below 1.0 x 106 cells/mL. Cells were counted daily 
using a hemacytometer (Reichert, Buffalo, NY) with Trypan Blue Stain 0.4% (Gibco). 
Isolation of total RNA. 5-10 x 106 cells were pelleted at 1250 rpm and then homogenized 
in 1 mL TRIzol reagent (Invitrogen). Resuspended cells were incubated for 5 minutes at 
room temperature then 0.2 mL chloroform was added per 1 mL TRIzol reagent. Samples 
were vigorously shaken and allowed to stand at room temperature for 2 minutes. 
Samples were then centrifuged at 12,000 RPM at 4°C for 15 minutes. The aqueous phase 
was transferred to a new tube and 0.5 mL isopropanol added, then incubated at room 
temperature for 10 minutes. Samples were centrifuged at 12,000 RPM at 4°C for 10- 
15min, supernatant removed and washed once with 75% EtOH. The RNA pellet was 
resuspended in DEPC-H2O and stored at -70°C until used. 
Polymerase Chain Reaction (PCR). 100 ng of total RNA was mixed with 50 mg of oligo 
dT, denatured at 65°C for 10 minutes, and mixed with reverse transcription buffer, 
dNTPs, RNAsin, and dithiothreitol (DTT) in a final volume of 50 pL. Reactions were 
then incubated with reverse transcriptase for 1 hour at 37°C. 1 pL of the resultant cDNA 
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was then subjected to 30-40 cycles of PCR under standard conditions with 100 ng of 
appropriate primers and 1 to 3 U Taq Polymerase. 
Preparation of nuclear extracts. 1.0 x 107 cells were centrifuged at 4°C. Cells were 
washed twice in ice-cold phosphate buffered saline (PBS) and once in Buffer A (10 
mmol/L HEPES-KOH (pH 7.9), 1.5 mmol/L MgCl2, 10 mmol/L KC1, 0.5 mmol/L DTT, 
and 0.5 mmol/L phenylmethylsulfonyl fluoride (PMSF). Cells were then lysed following 
a 5-minute incubation on ice in Buffer A with 0.1% Nonidet P-40, and then centrifuged at 
4°C for 15 minutes to recover nuclei. Nuclei were then lysed in high-salt Buffer C (20 
mmol/L HEPES-KOH (pH 7.9), 10% glycerol, 420 mmol/L NaCl, 10 mmol/L KC1, 0.2 
mmol/L EDTA, and 0.5 mmol/L DTT) and nuclear extracts were recovered by 
centrifugation for 15 minutes at 4°C. Aliquots of nuclear protein were analyzed for total 
protein concentration, then frozen immediately and stored at -70°C until used. 
Preparation of whole cell extracts. 1x10 cells were centrifuged at 4°C. Cells were 
washed once with 4°C phosphate buffered saline (PBS) and resuspended in 100 pL RIPA 
Lysis Buffer (Upstate Biotechnology, Lake Placid, NY) with protease inhibitor. Cells 
were incubated on ice for 30 minutes, then centrifuged at 10,000 x g for 10 minutes in 
4°C. The supernatant was transferred to a new tube, analyzed by spectrophotometry for 
concentration, and frozen immediately on dry ice. Samples were maintained at -70°C 
until used. 
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Western Blot. 15 pg protein were separated on a 4-12% Bis-Tris Gel (Invitrogen) and 
transferred to PVDF membrane (Immobilon-P; Millipore, Bedford, MA). Membranes 
were blocked in TST (20mM Tris [ph 7.5], 150 mL NaCl, 0.1% Tween-20) with 5% 
nonfat dry milk for 1 hour at 25°C. For detection of CDP, a mouse monoclonal antibody 
was incubated with the membrane in TST/5% milk overnight at 4°C at a concentration of 
1:1000. Rabbit anti-mouse secondary antibody was applied at a concentration of 1:3000 
and signals were detected using the enhanced chemiluminescent technique (Boehringer 
Mannheim). 
Northern Blot. 10 pg total RNA was separated on a 1% denaturing gel, transferred to 
nitrocellulose filters, and hybridized to 32P-labelled cDNA fragments at 42°C in 50% 
formamide. The filters were washed at in high stringency 0.1% SDS and 0.1X SSC at 
55°C and autographed. Blots were probed with a 600-bp mouse LF probe cloned in our 
laboratory. 
Quantitative PCR (Q-PCR). cDNA was prepared as above and adjusted to concentration 
of 10 ng/pL. 2 pL sample cDNA was incubated with lOOng of appropriate primers and 
25 pL iQ SYBR Green Supermix (Bio-Rad) to a total volume of 50pL. PCR was 
performed on a Bio-Rad Thermocycler at appropriate annealing conditions for a total of 
40 cycles. 
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Results 
CDP shRNA constructs were first tested for their ability to reduce CDP levels by 
transient transfection in fibroblast cell lines. NIH-3T3 cells are murine fibroblast cells 
that express little endogenous CDP in whole cell lysates. Cotransfections of CDP 
expression plasmids with two different shRNA constructs successfully decreased 
expression of ectopically expressed CDP as demonstrated by both western blot and RT- 
PCR (Figure 6). I have found that the shRNA at the 5’ end of the RNA transcript 
(shRNA 1) is the most efficient at knocking down gene expression by RT-PCR. 
However, by western blot it appears that the shRNA located at the 3’ end of the RNA 
transcript was more efficient at CDP knock-down. The combination of the two plasmids 
appears to be even more efficient at decreasing CDP levels. Three human CDP shRNA 
constructs were also tested in HeLa cells with similar results (data not shown). 
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Figure 6. Western blot and RT-PCR demonstrate decrease in CDP expression with 
shRNA constructs in NIH 3T3 cells. NIH 3T3 cells were transiently transfected with 
murine CDP expression plasmid alone, and CDP in combination with shRNA vectors. 
(A) Western blot of transfected NIH 3T3 cells shows decreased CDP expression with 
shRNA vectors. (B) RT-PCR also shows decreased levels of CDP expression in cells 
containing shRNA 1. 
Although many cell lines have been shown to express endogenous CDP, it is found at 
very low levels in whole cell extracts, which is characteristic of transcription factors. To 
assess the expression of endogenous CDP in human and mouse myeloid cells, I 
performed a western blot using NB4 whole cell extracts, as well as whole cell extracts 
and nuclear extracts of 32D cells (Figure 7). NB4 cells show endogenous expression of 
CDP on western blot with whole cell extracts. CDP is undetectable in whole cell lysates 
of 32D cells, but is easily detected in nuclear extracts. 
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Figure 7. Western blot of NB4 and 32D cells for CDP. Lane 1 NB4 whole cell 
extracts uninduced. Lane 2 NB4 whole cell extract induced with ATRA day 3. Lane 3 
32D nuclear extract uninduced. Lane 4 32D nuclear extract induced with G-CSF day 4. 
Lane 5 32D whole cell extract uninduced. Lane 6 32D whole cell extract induced with 
G-CSF day 4. 
A high degree of cell death is seen after induction of 32Dcl3 cells, reflecting stochastic 
variation in the level of G-CSF expression. To alleviate this problem, 32Dwtl8 cells 
have been previously generated. These cells express a chimeric G-CSF receptor with the 
intracellular domain of the G-CSF linked to the extracellular erythropoietin binding 
domain of the erythropoietin receptor. As these cells exhibit much less cell death on 
differentiation with erythropoietin, I used 32Dwtl8 cells to generate stable cell lines. 
After generating a pooled population of CDP shRNA expressing cells, I assessed the 
growth characteristics of control and CDP shRNA containing 32Dwtl8 cells by cell 
counting (Figure 8). 32Dwtl8 cells expressing the shRNA 1 construct do not have 
different growth characteristics than those containing the empty MigRl vector. Cells in 
regular GM continue to grow at an exponential pace, while cells induced to differentiate 

with EPO in IM have a longer doubling time. Those cells that were maintained in IM 
without IL-3 did not grow, and were too few to count after 3 days. 
18 
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Figure 8. Growth curve of 32Dwtl8 cells transfected with MigRI vector alone 
versus shRNA 1. 32Dwtl8 cells are an IL-3 dependent cell line which undergoes 
differentiation along the neutrophil lineage upon induction with EPO in the absence of 
IL-3. Cells transfected with shRNA remain IL-3 dependent, as evidenced by lack of 
growth in IL-3 deficient IM. Transfected cells show no significant differences in growth 
characteristics in GM and upon induction with EPO. 
After cells were sorted twice for GFP, I performed RT-PCR to look at LF in uninduced 
and induced cells. After 22 cycles of PCR, lactoferrin remained undetectable in 
uninduced cells containing the MigRI vector (Figure 9). MigRI cells then showed 

19 
normal upregulation of LF following induction with EPO. However, the cells containing 
CDP shRNA did show expression of LF at day 0. 
c 
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ShRNA 1 
DO D4 
Lactoferrin 
p-actin 
Figure 9. RT-PCR demonstrates LF expression at day 0 in 32Dwtl8 cells expressing 
shRNA 1. 32Dwtl8 cells are induced to differentiate with EPO and are shown at day 0 
and day 4. Expression of LF at day 0 is not seen in cells expressing MigRI vector alone, 
but is seen in cells expressing shRNA 1 construct. Both cells express LF following 
induction with EPO. 
To further quantify this difference in LF expression in day 0 cells, I performed a northern 
blot on the same cells. Again, LF expression was absent in uninduced cells containing 
MigRI alone (Figure 10). LF was normally upregulated in these cells by day 4. 
However, in CDP shRNA cells LF expression was again seen in day 0 cells. 
Densitometry analysis was then performed, and demonstrated a 14-fold increase in LF 
expression at day 0. Quantitative expression of LF at day 4 was unchanged. 
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Figure 10. Northern analysis demonstrates increased LF expression at day 0. (A) 
RNA extracts from wtl8 cells transfected with MigRI and shRNAI were analyzed by 
northern blot. LF expression is seen at day 0 in cells expressing shRNA, but not in cells 
expressing MigRI vector alone. (B) Densitometry analysis of northern blot shows a 14- 
fold increase in LF expression at day 0 in shRNA expressing cells relative to MigRI. 
Relative expression of LF at day 4 remains unchanged. 
To characterize the effect of CDP knock-down in other CDP-regulated genes I performed 
Q-PCR of cDNAs from MigRI and CDP shRNA cell lines for CDP, LF, C/EBPs, and 
gp91-phox. Q-PCR demonstrated a 3.9-fold decrease in CDP expression with 
approximately a 12-fold increase in LF expression (Figure 11). Expression of C/EBPc 
and gp91-phox was unchanged following CDP knock-down. 
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Figure 11. Q-PCR demonstrates decreased CDP expression and increased LF 
expression in shRNA clone relative to MigRl controls. Q-PCR confirms a 3.9-fold 
decrease in CDP expression in shRNA expressing cells relative to MigRl cells at day 0. 
LF expression is also increased 11.8-fold relative to MigRl. Expression of other CDP- 
regulated genes such as gp91-phox and C/EBP epsilon remains unchanged. 
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Discussion 
Generation of cell lines 
I employed both positive and negative selection strategies in an attempt to create stable 
cell lines expressing CDP shRNA. I performed cotransfections of my shRNA constructs 
in the MigRl vector (shRNA 1, shRNA 2, and a combination of shRNA 1+2) with 
empty pBabe-puro vector in a 10:1 ratio, and selected these cells in puromycin to 
generate stable cell lines. However, given that 32Dwtl8 cells have a very low 
transfection efficiency, on initial inspection of these cells I saw very few GFP-expressing 
cells. In addition, after initial high rates of cell death upon addition of puromycin, the 
transfected cells did not regrow. 
The shRNA PCR fragment itself also contains a gene for zeocin resistance (Figure 4). 
Again, 32Dwtl8 cells transfected with shRNA constructs did not regrow following 
addition of zeocin. In conversations with other groups who used the same technique to 
generate shRNA constructs for various target genes, they have similarly identified 
difficulties in selecting with zeocin. Possible difficulties with the zeocin resistance gene 
include inadequate expression or modification of the gene locus which do not allow 
resistance to zeocin. 
Since the shRNA construct is in the GFP-containing MigRl vector, we performed flow 
cytometry sorting for GFP expression as an alternative to antibiotic selection. This 
demonstrated the very low transfection efficiency of 32Dwtl8 cells, since only 0.35- 
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0.55% of cells had GFP expression by flow cytometry. GFP may be expressed at low 
levels undetectable by microscopy, or the U6 shRNA promoter may compete with the 
LTR promoter which drives GFP expression. The latter is unlikely, since the shRNA is 
driven from a RNA polymerase III promoter and GFP expression is driven from a RNA 
polymerase II promoter (see Figure 5). This positive selection for GFP was the most 
fruitful method to produce cells stably expressing CDP shRNA. The second sort by flow 
cytometry yielded adequate purity to allow analysis of the cell lines, as approximately 
70% of the cells were then GFP positive. The third flow cytometry sort generated cells 
that were 99.97% GFP positive, allowing for generation of the final data. During all 
FACS analysis, strict gating criteria were used in order to maximize the number of GFP 
positive cells. This strict criterion allows for the possibility that even more cells were 
GFP positive, albeit at lower levels of expression. 
Cell Growth 
After cells were sorted for the third time, they continued to grow normally for 
approximately 2 weeks, then died rapidly. After repeating flow cytometry several times, 
the cells continued to die when they were approximately 99% GFP positive. Cells grown 
in the same growth medium and incubator that were not sorted a third time, and were thus 
approximately 70% GFP positive, continued to maintain normal doubling times and 
growth characteristics. These cells remained approximately 70% GFP positive after a 
period of growth in culture, suggesting that GFP negative cells do not outgrow those 
expressing GFP. A trans-effect whereby the GFP negative cells support growth of GFP 
positive cells is not likely, as CDP is not known to have any extracellular effects. One 
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hypothesis is that a minimal amount of CDP is essential for normal growth and cell 
division. When no CDP is available to the cell, it will cease growth. Since CDP is 
known to have many roles within the cell and at different times in differentiation, this 
could mean that CDP is essential for proper cell growth and division. 
In addition to generating a pooled population of cells expressing the CDP shRNA 
construct, a monoclonal population was generated by sorting single cells into wells on 
96-well plates. This was performed after the second enrichment for GFP. Single cell 
clones were successfully generated, and several clones were expanded. After Q-PCR 
testing of these clonal cell lines, it was apparent that some cell lines repressed CDP 
expression better than others. Q-PCR analysis of these clones showed that they were also 
the most efficient at upregulating LF expression. However, after approximately one 
week in culture, clones with the lowest levels of CDP ceased to grow and began to die. 
Data from these cell clones and from cell pools discussed above suggest that CDP may 
indeed have an impact on cell growth. Very low or absent levels of CDP expression may 
contribute to an apoptotic signal within the cell. Alternatively, high level expression of 
CDP-regulated genes such as LF or other yet unknown factors may negatively influence 
the growth curve of cells lacking CDP. These possibilities are being actively investigated 
in the laboratory. 
As it has been suggested that CDP may be a tumor suppressor gene product, I performed 
cell counts to generate a growth curve for cells containing CDP shRNA and MigRl 
alone. Since this was impossible to perform on the clonal cell populations with the 
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lowest levels of CDP, I performed the analysis on pooled cell populations after the 
second enrichment for GFP. No significant differences in growth characteristics were 
seen between the two cell types. Cells in growth medium continued to divide 
exponentially while the growth of those induced to differentiate exhibited a plateau in 
growth. This was expected, as cells lose proliferative capacity as they differentiate. In 
addition, CDP shRNA containing cells remain IL-3 dependent. If CDP were indeed a 
tumor suppressor, one possible effect of repressing CDP could be that this IL-3 
dependent cell line could become independent of IL-3. Our results do not support this 
hypothesis, as cells quickly died in the absence of IL-3. The theory that CDP is a tumor 
suppressor is not supported here, although much more data are required to fully analyze 
this potential role. However, this is potentially at odds with the data that show growth 
inhibition in both clonal and pooled cell populations with highly effective CDP knock¬ 
down. Although the knock-down of CDP did not change initial growth characteristics of 
the cells, the possibility exists that cells cannot grow and divide for a long period of time 
without CDP. In addition, intermediate levels of CDP expression may be adequate to 
permit cell growth while allowing LF expression. 
Effect of CDP knock-down 
CDP is known to be expressed in actively dividing cells, and is thought to repress the 
expression of genes required in terminally differentiated cells. Although preliminary 
studies did not suggest that CDP overexpression affects morphologic differentiation, the 
effect of loss of CDP expression remains unknown. Cytospins of uninduced and induced 
cells did not show any morphological difference between control cells and CDP knock- 
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down cells. It is likely that morphological differentiation and chromatin condensation is 
controlled by different mechanisms than biochemical maturation. 
Western blot data showing decreased CDP expression in cells containing CDP shRNA is 
supported by Q-PCR data. One single cell clone containing shRNA 1 indicated a 4-fold 
decrease in CDP expression. Other single-cell clones also confirmed this data, albeit 
with varying levels of CDP knock-down. RNAi is known to generate clones with 
varying levels of expression. As previously mentioned, cells with the highest level of 
CDP knock-down did not grow long enough to expand for complete analysis. For this 
reason, I tested many clones before picking a few which best repressed CDP expression 
while maintaining adequate cell growth. 
The RT-PCR data show that LF is undetectable in control MigRl clones after 22 cycles 
of PCR, and is expressed at day 4 following induction. This is expected, as immature 
wild-type myeloid cells do not express SGPs until they are induced to differentiate. SGP 
expression can normally be seen following induction with a differentiating agent. 
However, in the CDP shRNA cell clones we can see expression of LF at day 0. This 
suggests that CDP may be the major repressor of LF expression in maturing granulocytes. 
Although CDP knock-down has the effect of upregulating LF expression at day 0, the 
expression of LF at day 4 of induction was unchanged from control cells. This was a 
somewhat unexpected result, since it has been clearly shown that C/EBPc, a transcription 
factor expressed in myeloid progenitors beyond the promyelocyte stage, is an important 
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inducer of SGP expression. This result could be accounted for in a few ways. The main 
transactivator of LF expression, C/EBPs, is expressed prior to induction of 
differentiation. If CDP is indeed the sole repressor of LF, then one could postulate that 
releasing the cell from CDP regulation following induction of differentiation may put the 
cell at maximum producing capacity for production of LF. If this were the case, LF 
expression in day 4 control cells would be at its maximum level. Indeed, CDP knock¬ 
down cells may also be at their maximum production capacity in their uninduced state. 
Another reason we may detect similar levels of LF expression in day 4 cells is that the 
sensitivity for detecting these high levels of expression may be low. Densitometry is not 
sensitive for detecting high levels of expression, as the blot may appear overexposed. It 
may be necessary to examine a less exposed blot to reevaluate this comparison. However, 
Q-PCR has the ability to detect more subtle changes in expression, and we can confirm 
the data by Q-PCR. 
CDP shRNA single cell clones were also tested for expression of other CDP regulated 
proteins, such C/EBPs and gp91-phox. No changes in expression of C/EBPs and gp91- 
phox were seen in these cell lines. This may suggest that genes expressed earlier in 
development may have a more complex mechanism of negative regulation. As CDP will 
still be expressed in the cell up to the point of LF expression, these genes may require the 
removal of an additional negative regulator to allow their expression. CDP is also a 
complex protein, with a variety of mechanisms of action. Different combinations of cut 
repeats and the homeodomain, in addition to the recruitment of histone deacetylaces and 
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phosphorylation, have been proposed as possible mechanisms of action. While it appears 
by both PCR and western blot that we are able to knock-down the entire protein, it may in 
fact be that we are knocking down only the part of the protein responsible for repressing 
LF expression. Alternatively, the small amount of CDP remaining in the cell may have a 
higher affinity for the early promoters. This change in affinity may be determined by the 
post-translational modifications discussed above. 
Human Cell Lines 
I also generated three shRNA constructs targeting the human CDP gene, with the goal of 
expression in NB4 cells. NB4 are a human cell line which contains the t(15:17) PML- 
RARa translocation. These cells do not express SGPs following induction to 
differentiate, and CDP has been found to remain bound to the LF promoter following 
induction. However, morphological differentiation is not affected. We have previously 
hypothesized that one of the changes associated with leukemic transformation is a 
disruption of the post-translational modification of CDP, as reflected in the failure to 
release CDP binding to the LF promoter upon induced maturation. We hypothesized that 
removal of CDP would permit expression of LF and the other SGPs in this cell line. 
However, we were unable to generate even a pooled cell population of human CDP 
shRNA-containing NB4 cells. NB4 cells were appropriately transfected and sorted for 
GFP expression. These cells were expanded following the first enrichment for GFP, but 
following the second selection, cells ceased to proliferate. This was attempted several 
times by several different members of the laboratory without success. We may attempt to 
generate these cells using antibiotic selection, or by cloning very early in methylcellulose. 
. 
29 
However, CDP expression in these cells may be required for cell growth and we may 
have to explore an alternative approach for analyzing the role of CDP in NB4 cells. 
Conclusions 
Although the role of human CDP knock-down has yet to be explored, I have successfully 
shown that both human and murine CDP shRNA constructs are effective at knocking 
down CDP expression in fibroblast cell lines. Expression of LF can be seen by RT-PCR, 
Q-PCR and northern blot in uninduced 32Dwtl8 cells containing shRNA constructs, 
suggesting that CDP plays a critical role in the negative regulation of LF. However, 
expression of other CDP-regulated genes, such as gp91-phox and C/EBPe remains 
unchanged. This suggests that LF expression reflects the direct modulation of CDP 
binding to its promoter, not an indirect effect of C/EBPs expression. The data on the role 
of CDP in cell growth have not been fully explored. Data from pools of transfected cells 
does not seem to support the theory that CDP may function as a tumor suppressor, yet 
low or absent levels of CDP seem to contribute to a cell death phenotype in both 
32Dwtl8 and NB4 cells. The results suggest that CDP can function as the sole negative 
regulatory element for LF gene expression, and that relief of CDP repression can increase 
LF expression independent of increased binding of positive regulatory factors. 
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Future Directions 
To elucidate some of the more subtle differences in gene expression, we will perform 
cDNA microarray analysis using a myeloid specific cDNA microarray generated in the 
Berliner Lab in collaboration with Dr. Arch Perkins (Dept of Pathology, Yale University 
School of Medicine). The results of this microarray will shed light on all genes regulated 
by CDP during myeloid differentiation, and will provide valuable and more complete 
information on the role CDP plays in the developing neutrophil. From here, we can 
further direct our studies on neutrophil-specific gene expression. 
Human NB4 cells, which harbor the t(l 5; 17) PML-RARa translocation, do not express 
SGPs even after induction to differentiate with ATRA. However, morphological 
differentiation is not affected. In these cells, CDP has been found to continually bind to 
the LF promoter following morphological differentiation. I have generated three human 
CDP shRNA constructs and tested them for CDP knock-down in HeLa cells. However, 
we have encountered difficulty in placing these constructs in NB4 cells. Stable NB4 cell 
lines expressing these constructs need to be generated, and a similar analysis of NB4 
CDP shRNA cell lines will be conducted. We hypothesize that the knock-down of CDP 
in these NB4 cells will allow expression of LF as well as other SGPs. 
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